Eli Lilly Says Antibody Reduces Need For Hospitalization For Moderate Covid-19 Patients
Last edited Wed Sep 16, 2020, 12:45 PM - Edit history (1)
'Lilly says antibody reduces need for hospitalization for moderate COVID-19 patients.' Deena Beasley, Reuters, 9/16/20.
(Reuters) - Eli Lilly & Co said on Wednesday that its experimental antibody reduced the need for hospitalization and emergency room visits for patients with moderate COVID-19, according to an interim analysis of a mid-stage clinical trial. The study tested three different doses of LY-CoV555, a manufactured antibody designed to recognize and lock onto the novel coronavirus, preventing the infection from spreading.
Of the total 302 patients treated with three different doses of LY-CoV555, five of them, or 1.7%, had to be admitted to a hospital or visit a hospital emergency room. That compares with a rate of 6%, or 9 out of 150, for trial patients given a placebo, the company said. Only the middle dose, 2,800 milligrams, achieved the trial’s main goal of reducing the amount of virus detected in patients compared to a placebo 11 days after treatment, it added.
No drug-related serious adverse events were reported and there have been no trial deaths.
Lilly said it expects to publish the results of the interim analysis in a peer-reviewed journal and discuss appropriate next steps with global regulators. The company said most hospitalizations occurred in patients with underlying risk factors such as being elderly or obese, suggesting a more pronounced treatment effect for people in these higher-risk groups. ~
https://www.reuters.com/article/us-health-coronavirus-lilly-antibody/lilly-says-antibody-reduces-need-for-hospitalization-for-moderate-covid-19-patients-idUSKBN2671TA
_________
Also: 'An Experimental Drug Protects Covid-19 Patients, Eli Lilly Claims.' NYT, Sept. 16, 2020.
https://democraticunderground.com/10142583293
